Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiopharmaceuticals | 48 | 2016 | 181 | 2.620 |
Why?
|
Technetium | 44 | 2016 | 68 | 2.600 |
Why?
|
Organotechnetium Compounds | 22 | 2013 | 28 | 1.910 |
Why?
|
Morpholinos | 28 | 2016 | 50 | 1.750 |
Why?
|
Morpholines | 26 | 2011 | 86 | 1.650 |
Why?
|
Peptides | 11 | 2013 | 549 | 1.410 |
Why?
|
Tissue Distribution | 55 | 2022 | 287 | 1.320 |
Why?
|
Antigens, Neoplasm | 7 | 2013 | 133 | 1.310 |
Why?
|
Glycoproteins | 6 | 2013 | 187 | 1.240 |
Why?
|
Biotin | 15 | 2011 | 51 | 1.080 |
Why?
|
Peptide Library | 5 | 2012 | 35 | 1.070 |
Why?
|
Indium Radioisotopes | 27 | 2015 | 41 | 1.040 |
Why?
|
Streptavidin | 16 | 2012 | 32 | 0.940 |
Why?
|
Mice | 89 | 2022 | 10301 | 0.920 |
Why?
|
Isotope Labeling | 33 | 2012 | 68 | 0.920 |
Why?
|
Antibodies | 7 | 2012 | 179 | 0.740 |
Why?
|
Radionuclide Imaging | 33 | 2008 | 121 | 0.740 |
Why?
|
Animals | 96 | 2022 | 19667 | 0.740 |
Why?
|
DNA, Antisense | 11 | 2009 | 17 | 0.720 |
Why?
|
Neoplasms | 18 | 2022 | 1232 | 0.710 |
Why?
|
Klebsiella pneumoniae | 3 | 2016 | 26 | 0.700 |
Why?
|
Colonic Neoplasms | 15 | 2011 | 215 | 0.690 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 11 | 2016 | 205 | 0.680 |
Why?
|
Oligonucleotides, Antisense | 4 | 2016 | 137 | 0.670 |
Why?
|
Mice, Nude | 28 | 2015 | 259 | 0.580 |
Why?
|
Oligonucleotides | 12 | 2010 | 215 | 0.580 |
Why?
|
Antibodies, Neoplasm | 13 | 2010 | 26 | 0.580 |
Why?
|
Organometallic Compounds | 6 | 2015 | 63 | 0.560 |
Why?
|
Cell Line, Tumor | 29 | 2015 | 1368 | 0.560 |
Why?
|
Klebsiella Infections | 1 | 2016 | 21 | 0.520 |
Why?
|
Technetium Tc 99m Mertiatide | 7 | 2004 | 7 | 0.520 |
Why?
|
RNA, Ribosomal | 1 | 2016 | 53 | 0.520 |
Why?
|
Drug Delivery Systems | 15 | 2012 | 312 | 0.500 |
Why?
|
Neoplasms, Experimental | 9 | 2010 | 75 | 0.480 |
Why?
|
Bacterial Infections | 3 | 2015 | 140 | 0.470 |
Why?
|
Fluorescent Dyes | 7 | 2015 | 196 | 0.460 |
Why?
|
Chelating Agents | 16 | 2012 | 46 | 0.450 |
Why?
|
Edetic Acid | 5 | 2008 | 21 | 0.430 |
Why?
|
Diagnostic Imaging | 3 | 2011 | 244 | 0.420 |
Why?
|
RNA, Bacterial | 1 | 2013 | 68 | 0.420 |
Why?
|
Positron-Emission Tomography | 8 | 2012 | 200 | 0.410 |
Why?
|
RNA, Ribosomal, 28S | 1 | 2012 | 3 | 0.410 |
Why?
|
Lung Diseases, Fungal | 1 | 2012 | 33 | 0.400 |
Why?
|
RNA, Fungal | 1 | 2012 | 38 | 0.400 |
Why?
|
Aspergillus fumigatus | 1 | 2012 | 52 | 0.390 |
Why?
|
Radioisotopes | 9 | 2010 | 23 | 0.390 |
Why?
|
Pentetic Acid | 9 | 2010 | 32 | 0.380 |
Why?
|
Nanoparticles | 9 | 2012 | 493 | 0.380 |
Why?
|
Biomarkers, Tumor | 6 | 2008 | 461 | 0.380 |
Why?
|
Escherichia coli Infections | 4 | 2004 | 86 | 0.370 |
Why?
|
Antibodies, Monoclonal | 13 | 2012 | 836 | 0.370 |
Why?
|
Leukocyte Elastase | 3 | 2001 | 13 | 0.370 |
Why?
|
Kidney | 8 | 2013 | 414 | 0.360 |
Why?
|
Bacterial Proteins | 6 | 1997 | 738 | 0.350 |
Why?
|
Picolinic Acids | 3 | 2015 | 7 | 0.340 |
Why?
|
Bacteriophages | 2 | 2008 | 54 | 0.340 |
Why?
|
Radioimmunodetection | 4 | 2000 | 4 | 0.320 |
Why?
|
Oligopeptides | 7 | 2006 | 128 | 0.320 |
Why?
|
Sodium Pertechnetate Tc 99m | 2 | 2008 | 3 | 0.310 |
Why?
|
Carcinoembryonic Antigen | 10 | 2007 | 32 | 0.290 |
Why?
|
Tomography, X-Ray Computed | 8 | 2022 | 1513 | 0.290 |
Why?
|
Rhenium | 7 | 2010 | 8 | 0.290 |
Why?
|
Microscopy, Fluorescence | 5 | 2016 | 394 | 0.290 |
Why?
|
Chromatography, High Pressure Liquid | 19 | 2015 | 226 | 0.290 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2011 | 178 | 0.270 |
Why?
|
Staphylococcal Infections | 4 | 2003 | 125 | 0.270 |
Why?
|
HT29 Cells | 3 | 2011 | 28 | 0.260 |
Why?
|
Bacteria | 1 | 2008 | 278 | 0.240 |
Why?
|
Gene Targeting | 5 | 2006 | 78 | 0.240 |
Why?
|
Fluorescence | 5 | 2011 | 83 | 0.230 |
Why?
|
Succinimides | 6 | 2002 | 17 | 0.230 |
Why?
|
Bacteriophage M13 | 1 | 2004 | 2 | 0.230 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 152 | 0.230 |
Why?
|
Myositis | 1 | 2004 | 5 | 0.230 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 16 | 0.220 |
Why?
|
Metabolic Clearance Rate | 13 | 2007 | 47 | 0.220 |
Why?
|
Male | 38 | 2015 | 27784 | 0.220 |
Why?
|
Neoplasm Transplantation | 10 | 2011 | 161 | 0.220 |
Why?
|
DNA, Single-Stranded | 4 | 1997 | 100 | 0.210 |
Why?
|
DNA Probes | 2 | 2009 | 35 | 0.210 |
Why?
|
Serpins | 2 | 2000 | 17 | 0.210 |
Why?
|
Bone Morphogenetic Protein Receptors | 2 | 2013 | 14 | 0.200 |
Why?
|
Amino Acid Sequence | 3 | 2011 | 1555 | 0.200 |
Why?
|
Smad3 Protein | 2 | 2013 | 17 | 0.200 |
Why?
|
Immunoglobulin G | 9 | 2006 | 446 | 0.200 |
Why?
|
Antineoplastic Agents | 5 | 2011 | 628 | 0.200 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2013 | 61 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2006 | 237 | 0.200 |
Why?
|
Technetium Compounds | 4 | 2009 | 5 | 0.190 |
Why?
|
Regeneration | 2 | 2013 | 93 | 0.190 |
Why?
|
Axonal Transport | 1 | 2022 | 31 | 0.190 |
Why?
|
Humans | 54 | 2022 | 59454 | 0.190 |
Why?
|
Base Sequence | 8 | 2013 | 1302 | 0.190 |
Why?
|
Indicators and Reagents | 3 | 2011 | 51 | 0.190 |
Why?
|
Molecular Sequence Data | 6 | 2011 | 1953 | 0.190 |
Why?
|
Transforming Growth Factor beta | 2 | 2013 | 170 | 0.190 |
Why?
|
DNA | 6 | 2010 | 805 | 0.190 |
Why?
|
Biological Products | 1 | 2022 | 90 | 0.180 |
Why?
|
Epidermal Growth Factor | 2 | 1998 | 48 | 0.180 |
Why?
|
Insulin-Secreting Cells | 2 | 2012 | 178 | 0.170 |
Why?
|
Species Specificity | 2 | 2012 | 329 | 0.170 |
Why?
|
Drug Carriers | 4 | 2009 | 175 | 0.170 |
Why?
|
Metal Nanoparticles | 1 | 2022 | 182 | 0.160 |
Why?
|
Biotinylation | 4 | 2012 | 36 | 0.160 |
Why?
|
Vitiligo | 1 | 2022 | 123 | 0.160 |
Why?
|
Immunoconjugates | 4 | 2010 | 85 | 0.160 |
Why?
|
Polymers | 4 | 2010 | 316 | 0.160 |
Why?
|
Peptide Fragments | 3 | 2008 | 401 | 0.160 |
Why?
|
Mice, Inbred Strains | 10 | 2010 | 180 | 0.160 |
Why?
|
Endocarditis, Bacterial | 1 | 1999 | 31 | 0.150 |
Why?
|
Staphylococcus aureus | 2 | 2013 | 170 | 0.150 |
Why?
|
Kidney Neoplasms | 5 | 2006 | 125 | 0.140 |
Why?
|
Autoradiography | 5 | 2001 | 53 | 0.140 |
Why?
|
Protein Binding | 6 | 2011 | 1555 | 0.140 |
Why?
|
Multimodal Imaging | 3 | 2012 | 64 | 0.140 |
Why?
|
Antibodies, Monoclonal, Humanized | 4 | 2012 | 217 | 0.140 |
Why?
|
Nucleic Acids | 1 | 1997 | 50 | 0.140 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2022 | 480 | 0.140 |
Why?
|
Flow Cytometry | 4 | 2011 | 645 | 0.130 |
Why?
|
Mice, Inbred BALB C | 4 | 2012 | 868 | 0.130 |
Why?
|
Osteomyelitis | 1 | 1996 | 24 | 0.130 |
Why?
|
Escherichia coli | 2 | 2013 | 695 | 0.130 |
Why?
|
Streptococcus pyogenes | 2 | 2015 | 27 | 0.130 |
Why?
|
Glycine | 3 | 2003 | 46 | 0.130 |
Why?
|
Breast Neoplasms | 6 | 2010 | 1118 | 0.120 |
Why?
|
Radiotherapy Dosage | 2 | 2013 | 81 | 0.120 |
Why?
|
Yttrium Radioisotopes | 2 | 2013 | 7 | 0.120 |
Why?
|
Molecular Imaging | 1 | 2015 | 46 | 0.120 |
Why?
|
Gene Products, tat | 2 | 2006 | 14 | 0.120 |
Why?
|
Skin | 2 | 2022 | 357 | 0.120 |
Why?
|
Thymus Gland | 1 | 2015 | 229 | 0.110 |
Why?
|
Half-Life | 2 | 2013 | 75 | 0.110 |
Why?
|
Disease Models, Animal | 5 | 2022 | 2051 | 0.110 |
Why?
|
Cell Death | 1 | 2015 | 271 | 0.110 |
Why?
|
Nucleic Acid Hybridization | 6 | 2009 | 99 | 0.110 |
Why?
|
Ascorbic Acid | 1 | 1994 | 46 | 0.110 |
Why?
|
Carbocyanines | 3 | 2010 | 29 | 0.110 |
Why?
|
Sensitivity and Specificity | 5 | 2011 | 1097 | 0.110 |
Why?
|
Blood Proteins | 5 | 2003 | 75 | 0.110 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2013 | 78 | 0.100 |
Why?
|
Rats | 5 | 2015 | 1911 | 0.100 |
Why?
|
Cysteine | 5 | 1997 | 107 | 0.100 |
Why?
|
Oligonucleotide Probes | 1 | 2012 | 43 | 0.100 |
Why?
|
Spores, Fungal | 1 | 2012 | 19 | 0.100 |
Why?
|
Nicotinic Acids | 2 | 2003 | 2 | 0.100 |
Why?
|
Hydrazines | 2 | 2003 | 10 | 0.100 |
Why?
|
Genes, erbB-2 | 1 | 2012 | 2 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2013 | 474 | 0.100 |
Why?
|
Avidin | 3 | 2010 | 11 | 0.100 |
Why?
|
Benzothiazoles | 2 | 2009 | 19 | 0.100 |
Why?
|
Quinolines | 2 | 2009 | 41 | 0.100 |
Why?
|
Organ Specificity | 7 | 2007 | 183 | 0.100 |
Why?
|
Heterocyclic Compounds | 1 | 2011 | 12 | 0.100 |
Why?
|
Injections, Intravenous | 4 | 2013 | 155 | 0.090 |
Why?
|
Vitamin B Complex | 1 | 2011 | 15 | 0.090 |
Why?
|
Streptococcal Infections | 1 | 2012 | 76 | 0.090 |
Why?
|
Radioimmunotherapy | 2 | 2009 | 7 | 0.090 |
Why?
|
Trastuzumab | 4 | 2012 | 11 | 0.090 |
Why?
|
Pharmacokinetics | 1 | 2011 | 6 | 0.090 |
Why?
|
Intestinal Mucosa | 2 | 2013 | 227 | 0.090 |
Why?
|
Glucaric Acid | 1 | 2011 | 2 | 0.090 |
Why?
|
Physics | 1 | 2011 | 12 | 0.090 |
Why?
|
Luminescence | 1 | 2011 | 18 | 0.090 |
Why?
|
Phosphorus Compounds | 1 | 2010 | 2 | 0.090 |
Why?
|
Chemical Fractionation | 1 | 2010 | 13 | 0.090 |
Why?
|
Isothiocyanates | 1 | 2010 | 14 | 0.090 |
Why?
|
Amines | 1 | 2010 | 29 | 0.090 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 2000 | 178 | 0.090 |
Why?
|
Thionucleotides | 3 | 2001 | 38 | 0.090 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 92 | 0.090 |
Why?
|
Lung | 2 | 2012 | 920 | 0.090 |
Why?
|
Iodine Radioisotopes | 1 | 2010 | 50 | 0.090 |
Why?
|
Liver | 5 | 2010 | 796 | 0.080 |
Why?
|
Inflammation | 4 | 2012 | 1099 | 0.080 |
Why?
|
Macaca mulatta | 2 | 2001 | 228 | 0.080 |
Why?
|
Chromatography, Gel | 4 | 2010 | 65 | 0.080 |
Why?
|
Surface Plasmon Resonance | 2 | 2007 | 33 | 0.080 |
Why?
|
Consensus Sequence | 1 | 2008 | 29 | 0.080 |
Why?
|
Polyamines | 1 | 2008 | 11 | 0.080 |
Why?
|
Forelimb | 1 | 2008 | 9 | 0.070 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2004 | 27 | 0.070 |
Why?
|
Cattle | 2 | 2000 | 304 | 0.070 |
Why?
|
Horse Diseases | 1 | 2008 | 22 | 0.070 |
Why?
|
DNA Primers | 1 | 2008 | 289 | 0.070 |
Why?
|
Salmonella enterica | 1 | 2008 | 26 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2008 | 323 | 0.070 |
Why?
|
Tumor Cells, Cultured | 5 | 2011 | 450 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 1 | 2008 | 100 | 0.070 |
Why?
|
Hydrazones | 1 | 2007 | 5 | 0.070 |
Why?
|
Blotting, Western | 1 | 2008 | 584 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 651 | 0.070 |
Why?
|
Organophosphorus Compounds | 1 | 2007 | 31 | 0.070 |
Why?
|
Rats, Wistar | 2 | 2015 | 179 | 0.070 |
Why?
|
Guanine | 1 | 2007 | 23 | 0.070 |
Why?
|
Nucleic Acid Heteroduplexes | 1 | 2006 | 15 | 0.070 |
Why?
|
Cell Nucleus | 1 | 2010 | 608 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 858 | 0.060 |
Why?
|
Niacinamide | 2 | 1996 | 32 | 0.060 |
Why?
|
Host-Pathogen Interactions | 1 | 2008 | 240 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2010 | 398 | 0.060 |
Why?
|
Drug Stability | 6 | 2004 | 141 | 0.060 |
Why?
|
Oligodeoxyribonucleotides | 2 | 1997 | 243 | 0.060 |
Why?
|
Female | 15 | 2015 | 30766 | 0.060 |
Why?
|
Algorithms | 2 | 2008 | 979 | 0.060 |
Why?
|
Aminobutyrates | 1 | 2004 | 10 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 411 | 0.060 |
Why?
|
Peptide Nucleic Acids | 2 | 2001 | 16 | 0.060 |
Why?
|
Sulfur Radioisotopes | 2 | 2001 | 12 | 0.060 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 339 | 0.060 |
Why?
|
Cell Line | 3 | 2012 | 1984 | 0.050 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 90 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2002 | 450 | 0.050 |
Why?
|
Molecular Weight | 2 | 2002 | 184 | 0.050 |
Why?
|
Cytosine | 1 | 2002 | 31 | 0.050 |
Why?
|
Whole Body Imaging | 2 | 2015 | 9 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2003 | 83 | 0.050 |
Why?
|
Integrins | 1 | 2003 | 106 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2003 | 805 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 14 | 0.050 |
Why?
|
Integrin alphaVbeta3 | 1 | 2002 | 14 | 0.050 |
Why?
|
Keratinocytes | 1 | 2022 | 63 | 0.050 |
Why?
|
Profilins | 1 | 2022 | 45 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 169 | 0.050 |
Why?
|
Models, Biological | 1 | 2007 | 1143 | 0.050 |
Why?
|
Nitriles | 1 | 2002 | 62 | 0.050 |
Why?
|
Area Under Curve | 2 | 2013 | 141 | 0.050 |
Why?
|
Culture Techniques | 2 | 2001 | 12 | 0.050 |
Why?
|
RNA, Antisense | 1 | 2001 | 49 | 0.050 |
Why?
|
Superoxide Dismutase-1 | 1 | 2022 | 133 | 0.050 |
Why?
|
Heterocyclic Compounds, 1-Ring | 2 | 2012 | 6 | 0.050 |
Why?
|
Liposomes | 1 | 2001 | 100 | 0.050 |
Why?
|
Receptor, ErbB-2 | 2 | 2012 | 49 | 0.040 |
Why?
|
Spinal Cord | 1 | 2022 | 195 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2000 | 69 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2022 | 213 | 0.040 |
Why?
|
Gold | 1 | 2022 | 225 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2012 | 574 | 0.040 |
Why?
|
Contrast Media | 1 | 2022 | 404 | 0.040 |
Why?
|
Mammography | 1 | 2022 | 271 | 0.040 |
Why?
|
Binding, Competitive | 2 | 1997 | 98 | 0.040 |
Why?
|
Phantoms, Imaging | 2 | 2011 | 217 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 1992 | 36 | 0.040 |
Why?
|
Reference Values | 2 | 2002 | 326 | 0.040 |
Why?
|
Gamma Cameras | 1 | 1999 | 6 | 0.040 |
Why?
|
Cell Membrane | 2 | 2015 | 487 | 0.040 |
Why?
|
Intracellular Space | 2 | 2009 | 34 | 0.040 |
Why?
|
Cells, Cultured | 4 | 2006 | 2095 | 0.040 |
Why?
|
Cross-Linking Reagents | 2 | 1996 | 117 | 0.040 |
Why?
|
RNA, Messenger | 3 | 2012 | 1469 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2022 | 1206 | 0.040 |
Why?
|
Aprotinin | 1 | 1998 | 12 | 0.040 |
Why?
|
Serine Proteinase Inhibitors | 1 | 1998 | 10 | 0.040 |
Why?
|
Antifibrinolytic Agents | 1 | 1998 | 15 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 1991 | 263 | 0.040 |
Why?
|
Cell Survival | 2 | 2010 | 559 | 0.040 |
Why?
|
Methods | 1 | 1997 | 41 | 0.030 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 1997 | 20 | 0.030 |
Why?
|
Myocardium | 1 | 1999 | 264 | 0.030 |
Why?
|
Microspheres | 2 | 2007 | 55 | 0.030 |
Why?
|
Drug Design | 1 | 1997 | 136 | 0.030 |
Why?
|
Heart | 1 | 1999 | 274 | 0.030 |
Why?
|
Structure-Activity Relationship | 2 | 2012 | 365 | 0.030 |
Why?
|
Indium | 2 | 1987 | 7 | 0.030 |
Why?
|
Biomarkers | 1 | 2022 | 1306 | 0.030 |
Why?
|
Temperature | 1 | 1997 | 296 | 0.030 |
Why?
|
Phosphatidylserines | 1 | 2015 | 13 | 0.030 |
Why?
|
Europium | 1 | 2015 | 1 | 0.030 |
Why?
|
Atrophy | 1 | 2015 | 76 | 0.030 |
Why?
|
Cricetulus | 1 | 2015 | 99 | 0.030 |
Why?
|
Biological Transport | 2 | 2009 | 288 | 0.030 |
Why?
|
CHO Cells | 1 | 2015 | 189 | 0.030 |
Why?
|
Metallothionein | 1 | 1995 | 8 | 0.030 |
Why?
|
Extremities | 1 | 2015 | 44 | 0.030 |
Why?
|
Optical Imaging | 1 | 2015 | 68 | 0.030 |
Why?
|
Dithionite | 1 | 1994 | 2 | 0.030 |
Why?
|
Kinetics | 4 | 2007 | 751 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1994 | 32 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 1994 | 48 | 0.030 |
Why?
|
Injections | 1 | 2013 | 76 | 0.030 |
Why?
|
Oxidation-Reduction | 3 | 2004 | 304 | 0.030 |
Why?
|
Proteins | 1 | 1999 | 730 | 0.030 |
Why?
|
Chronic Disease | 1 | 1996 | 717 | 0.030 |
Why?
|
Drug Interactions | 1 | 2013 | 115 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2013 | 46 | 0.030 |
Why?
|
Immunoglobulin Fragments | 1 | 1993 | 7 | 0.030 |
Why?
|
Antibodies, Antinuclear | 1 | 2013 | 36 | 0.030 |
Why?
|
Adsorption | 1 | 2013 | 82 | 0.030 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2012 | 4 | 0.030 |
Why?
|
STAT1 Transcription Factor | 1 | 2012 | 35 | 0.020 |
Why?
|
Lysine | 1 | 1992 | 77 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2003 | 89 | 0.020 |
Why?
|
Bone Morphogenetic Protein Receptors, Type II | 1 | 2012 | 5 | 0.020 |
Why?
|
Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 5 | 0.020 |
Why?
|
Captopril | 1 | 2012 | 9 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2013 | 126 | 0.020 |
Why?
|
Kidney Tubules | 1 | 2012 | 18 | 0.020 |
Why?
|
Biological Availability | 1 | 2013 | 195 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1992 | 33 | 0.020 |
Why?
|
Interferons | 1 | 2012 | 61 | 0.020 |
Why?
|
Diabetic Nephropathies | 1 | 2012 | 37 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2012 | 62 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2004 | 526 | 0.020 |
Why?
|
Fibrosis | 1 | 2012 | 153 | 0.020 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 142 | 0.020 |
Why?
|
Technetium Tc 99m Pentetate | 2 | 2001 | 11 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 2010 | 12 | 0.020 |
Why?
|
Animal Structures | 1 | 2010 | 5 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2010 | 7 | 0.020 |
Why?
|
Transfection | 1 | 2012 | 675 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2010 | 2 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2010 | 16 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 223 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2010 | 52 | 0.020 |
Why?
|
Mice, SCID | 1 | 2011 | 513 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 1995 | 674 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2009 | 51 | 0.020 |
Why?
|
Carcinoma | 1 | 1990 | 116 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2011 | 516 | 0.020 |
Why?
|
Abdomen | 1 | 2010 | 91 | 0.020 |
Why?
|
Aged | 6 | 1996 | 13424 | 0.020 |
Why?
|
Models, Structural | 1 | 2009 | 25 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 1996 | 5126 | 0.020 |
Why?
|
Spleen | 1 | 2010 | 480 | 0.020 |
Why?
|
Biological Assay | 1 | 2009 | 56 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2011 | 587 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2012 | 627 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2009 | 193 | 0.020 |
Why?
|
Dendrimers | 1 | 2008 | 11 | 0.020 |
Why?
|
Adult | 6 | 1996 | 15697 | 0.020 |
Why?
|
Middle Aged | 6 | 1996 | 16335 | 0.020 |
Why?
|
Nanotechnology | 1 | 2009 | 127 | 0.020 |
Why?
|
Horses | 1 | 2008 | 52 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2009 | 5287 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2008 | 124 | 0.020 |
Why?
|
Mice, Hairless | 1 | 2007 | 17 | 0.020 |
Why?
|
In Vitro Techniques | 2 | 2002 | 473 | 0.020 |
Why?
|
Organophosphates | 1 | 2007 | 16 | 0.020 |
Why?
|
Acids | 1 | 2007 | 14 | 0.020 |
Why?
|
Apoptosis | 1 | 2012 | 1033 | 0.020 |
Why?
|
Phosphates | 1 | 2007 | 90 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 3621 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 1997 | 291 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2006 | 133 | 0.020 |
Why?
|
Sugar Acids | 2 | 1996 | 7 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2006 | 178 | 0.020 |
Why?
|
Acid Phosphatase | 1 | 1985 | 8 | 0.020 |
Why?
|
Diffusion | 1 | 1985 | 82 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1985 | 100 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1990 | 584 | 0.010 |
Why?
|
Mercaptoethanol | 2 | 1996 | 4 | 0.010 |
Why?
|
Tin | 2 | 1996 | 3 | 0.010 |
Why?
|
Computer Simulation | 1 | 2007 | 459 | 0.010 |
Why?
|
Colon | 1 | 1985 | 136 | 0.010 |
Why?
|
Rectal Neoplasms | 1 | 1985 | 98 | 0.010 |
Why?
|
Citrates | 1 | 2003 | 17 | 0.010 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 13 | 0.010 |
Why?
|
Gallium | 1 | 2003 | 12 | 0.010 |
Why?
|
Umbilical Veins | 1 | 2003 | 13 | 0.010 |
Why?
|
Prodrugs | 1 | 2003 | 34 | 0.010 |
Why?
|
Radiotherapy | 1 | 2003 | 61 | 0.010 |
Why?
|
Acetonitriles | 1 | 2002 | 2 | 0.010 |
Why?
|
Conjugation, Genetic | 1 | 2001 | 16 | 0.010 |
Why?
|
Hot Temperature | 1 | 2002 | 126 | 0.010 |
Why?
|
Signal Transduction | 1 | 2012 | 2901 | 0.010 |
Why?
|
Subcellular Fractions | 1 | 2001 | 68 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2001 | 32 | 0.010 |
Why?
|
Cations | 1 | 2001 | 63 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2001 | 214 | 0.010 |
Why?
|
Pilot Projects | 1 | 2004 | 916 | 0.010 |
Why?
|
Protein Subunits | 1 | 2001 | 165 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 529 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2001 | 165 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2001 | 278 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 347 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2003 | 1560 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 490 | 0.010 |
Why?
|
Ions | 1 | 1992 | 52 | 0.010 |
Why?
|
Thigh | 1 | 1991 | 26 | 0.010 |
Why?
|
Models, Chemical | 1 | 1990 | 137 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 1991 | 276 | 0.000 |
Why?
|
Software | 1 | 1990 | 366 | 0.000 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1985 | 3 | 0.000 |
Why?
|
Antigen-Antibody Complex | 1 | 1985 | 51 | 0.000 |
Why?
|
Transferrin | 1 | 1985 | 67 | 0.000 |
Why?
|